Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...

(RTTNews) - Agios Pharmaceuticals Inc. (AGIO) announced that the U.S. Food and Drug Administration has approved AQVESME (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of anemia ...